Human olfactory mesenchymal stromal cell transplantation ameliorates experimental autoimmune encephalomyelitis revealing an inhibitory role for IL16 on myelination.

Abstract

One of the therapeutic approaches for the treatment of the autoimmune demyelinating disease, multiple sclerosis (MS) is bone marrow mesenchymal stromal cell (hBM-MSCs) transplantation. However, given their capacity to enhance myelination in vitro, we hypothesised that human olfactory mucosa-derived MSCs (hOM-MSCs) may possess additional properties suitable for CNS repair. Herein, we have examined the efficacy of hOM-MSCs versus hBM-MSCs using the experimental autoimmune encephalomyelitis (EAE) model. Both MSC types ameliorated disease, if delivered during the initial onset of symptomatic disease. Yet, only hOM-MSCs improved disease outcome if administered during established disease when animals had severe neurological deficits. Histological analysis of spinal cord lesions revealed hOM-MSC transplantation reduced blood-brain barrier disruption and inflammatory cell recruitment and enhanced axonal survival. At early time points post-hOM-MSC treatment, animals had reduced levels of circulating IL-16, which was reflected in both the ability of immune cells to secrete IL-16 and the level of IL-16 in spinal cord inflammatory lesions. Further in vitro investigation revealed an inhibitory role for IL-16 on oligodendrocyte differentiation and myelination. Moreover, the availability of bioactive IL-16 after demyelination was reduced in the presence of hOM-MSCs. Combined, our data suggests that human hOM-MSCs may have therapeutic benefit in the treatment of MS via an IL-16-mediated pathway, especially if administered during active demyelination and inflammation.

• Authors: Susan L Lindsay, Aleksandra M Molęda, Lindsay M MacLellan, Siew Min Keh, Daniel E McElroy, Christopher Linington, Carl S Goodyear, Susan C Barnett
• Journal: Acta neuropathologica communications (Acta Neuropathol Commun) Vol. 10 Issue 1 Pg. 12 (01 29 2022) ISSN: 2051-5960 [Electronic] England
• PMID: 35093166 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Interleukin-16

Topics

• Animals
• Encephalomyelitis, Autoimmune, Experimental (metabolism, therapy)
• Humans
• Interleukin-16 (metabolism)
• Mesenchymal Stem Cell Transplantation (methods)
• Mice
• Myelin Sheath (metabolism)
• Neurogenesis (physiology)
• Olfactory Mucosa (cytology)